| payload |
{"created_at":"2026-04-10T12:11:33.277 {"created_at":"2026-04-10T12:11:33.277556+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:1b6bdfbe8f3361a9","evidence_event_ids":["evt_62fdb8c5e319"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/2-recession-resistant-dividend-stocks-buy-now-while-theyre-still-cheap","as_of":"2026-04-10T12:11:33.277556+00:00","canonical_url":"https://www.fool.com/investing/2026/04/10/2-recession-resistant-dividend-stocks-to-buy-now-w/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/2-recession-resistant-dividend-stocks-buy-now-while-theyre-still-cheap","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_84a295ae23ccb638","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/10/2-recession-resistant-dividend-stocks-to-buy-now-w/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T12:14:30.802160+00:00","extraction_method":"heuristic","fetched_description":"Key PointsCVS Health and Bristol Myers Squibb are built to handle the toughest recessions.","fetched_title":"2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap | Nasdaq","final_url":"https://www.nasdaq.com/articles/2-recession-resistant-dividend-stocks-buy-now-while-theyre-still-cheap","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/2-recession-resistant-dividend-stocks-buy-now-while-theyre-still-cheap","source_event_id":"evt_62fdb8c5e319","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"1b90d760779e6265","kind":"unusual_volume","published_at":"2026-04-10T10:50:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 10, 2026","2008","past two decades","past 20 years"],"entities":[{"asset_class":"equity","name":"CVS Health","relevance":"high","symbol":"CVS","type":"company"},{"asset_class":"equity","name":"Bristol Myers Squibb","relevance":"high","symbol":"BMY","type":"company"},{"asset_class":"other","name":"The Motley Fool","relevance":"medium","symbol":"","type":"publisher"}],"event_type":"other","information_gaps":["No unusual trading volume data is provided (no volume ratio vs average, no direction, and no tickers tied to volume anomalies).","The signal type suggests a volume-delta discovery, but the article content is a valuation/dividend thesis rather than a volume/market microstructure report.","No explicit catalyst is stated for any volume change; the only catalyst-like discussion is macro/geopolitical risk (rising oil prices and geopolitical tensions) and company fundamentals (dividends, product pipeline).","No confirmation mechanism is described (e.g., whether volume is confirmed by news); the text does not mention volume at all."],"key_facts":["The article is dated April 10, 2026 (06:50 am EDT) and is written by Prosper Junior Bakiny for The Motley Fool.","CVS Health is described as having maintained its dividend program without resorting to payout cuts over the past 20 years (including 2008 and the pandemic-related disruption).","CVS is described as trading at 10.3x forward earnings versus a healthcare sector average of 16.8x.","Bristol Myers Squibb is described as trading at 9.5x forward earnings.","BMY is described as having not suspended or reduced its dividend in the past two decades.","The article states BMY has faced patent cliffs and will face more, but has launched new products; it specifically mentions a new subcutaneous version of Opdivo as a growth driver.","The article states Opdivo will soon run out of patent exclusivity, but the new formulation will not and should contribute to top line for years."],"numeric_claims":[{"label":"CVS forward earnings multiple","value":"10.3x"},{"label":"Healthcare sector average forward earnings multiple","value":"16.8x"},{"label":"BMY forward earnings multiple","value":"9.5x"}],"primary_claim":"CVS and BMY are presented as recession-resistant dividend stocks with relatively low forward earnings valuations (CVS 10.3x; BMY 9.5x).","relevance_score":0.25,"sentiment":"positive","source_quality":"high","summary":"The article argues that CVS Health (CVS) and Bristol Myers Squibb (BMY) are recession-resilient dividend stocks and appear attractively valued based on forward earnings multiples. It does not provide any unusual trading volume metrics or a volume-vs-average ratio.","topics":["recession resilience","dividends","valuation (forward earnings multiples)","healthcare","pharmacy/insurance (CVS)","pharmaceutical pipeline/patent cliffs (BMY)","Opdivo formulation update"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsCVS Health and Bristol Myers Squibb are built to handle the toughest recessions.","tickers":[],"title":"2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap","url":"https://www.fool.com/investing/2026/04/10/2-recession-resistant-dividend-stocks-to-buy-now-w/"}}... |